Who
Epperly Melissa B
Director
Company insider
Files Form 4 as: Director, Roivant Sciences; Director, Nautilus Biotechnology; Director, Kinnate Biopharma; Chief Financial Officer, Zentalis Pharmaceuticals.
In numbers
- Trades disclosed
- 126
- Buys
- 3
- Sells
- 22
- Bought
- $860K
- Sold
- $8.7M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 7 Apr 2020
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $79K17,750 at $4.46 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $608K16,850 at $36.08 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $33K900 at $36.57 | filing |
| 1 Oct 2026filed 5 Oct 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,750 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $172K4,338 at $39.65 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $24K600 at $40.38 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $172K4,338 at $39.65 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $24K600 at $40.38 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $89K2,179 at $40.94 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $89K2,179 at $40.94 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —543 at $0.00 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —543 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $79K17,750 at $4.46 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $515K15,002 at $34.32 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $95K2,748 at $34.71 | filing |
| 29 Jun 2026filed 1 Jul 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,750 at $0.00 | filing |
News
Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseROIV · rttnews.com · 21 Oct 2026Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)ROIV · dailypolitical.com · 14 Oct 2026Analyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS)ROIV · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Epperly Melissa B; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.